2025 Webinars I’ve Failed First Line Therapy, Now What?Thursday, October 16, 20257:00 – 7:30 pm (ET) When melanoma treatment stops working, knowing what to do next can feel uncertain. Join melanoma experts Allison Betof, MD, PhD of Stanford University and Melissa Wilson, PA-C, MPAS of UPMC Hillman Cancer Center and AIM’s Ask a Medical Expert, for a focused discussion on ... Read More| AIM at Melanoma Foundation
Founded in 2004, AIM at Melanoma is a global foundation dedicated to finding more effective treatments and, ultimately, the cure for melanoma.| AIM at Melanoma Foundation
A melanoma diagnosis can turn life upside down in an instant. While doctors focus on staging, biopsies, and treatment plans, patients are often left with unanswered questions about how to actually live with cancer. That gap is where peer support becomes not just helpful, but essential. In this episode of Beyond the Clinic: Living Well with Melanoma, host Dr. Samantha ... Read More The post The Power of Peer Support in Melanoma Survivorship appeared first on AIM at Melanoma Foundation.| AIM at Melanoma Foundation
A Free Educational Webinar for Melanoma Patients and CaregiversThursday, October 16 | 7:00–7:30 PM ET Facing melanoma can be overwhelming—especially when initial treatment doesn’t go as hoped. If you’ve recently learned that your first-line therapy has stopped working, or you’re supporting someone who has, you may be wondering what comes next. Our upcoming live webinar, “I’ve Failed First-Line Therapy – ... Read More| AIM at Melanoma Foundation
In this powerful episode, we’re joined by Dr. Wendy G. Lichtenthal, a leading expert in grief and bereavement care. Dr. Lichtenthal is the Founding Director of the Center for the Advancement of Bereavement Care at the Sylvester Comprehensive Cancer Center and Professor at the University of Miami Miller School of Medicine. A licensed clinical psychologist with over 20 years of ... Read More The post Caring Through Loss: A Conversation on Bereavement appeared first on AIM at Melanoma Foundation.| AIM at Melanoma Foundation
Hundreds of patients, families, and friends have shared their stories with AIM at Melanoma about the urgent need for access to RP1+nivolumab. We are grateful to everyone who contributed. Yesterday, along with several other melanoma organizations, we sent a letter to the FDA urging them to make RP1 available while remaining regulatory issues are addressed. The full letter is embedded ... Read More The post Advocating for Patients: Letter to the FDA on RP1 Treatment Access appeared first on AIM...| AIM at Melanoma Foundation
AIM at Melanoma proudly collaborates with our Canadian partner, the Save Your Skin Foundation on presenting this informational webinar on ocular/uveal melanoma. Date & Time: September 25, 7:00–7:30 PM (ET) Hosted by: Richard D. Carvajal, MD, Melanoma and Cutaneous Oncology, Early Drug Development, Northwell Health Cancer Institute Featuring: What You’ll Learn: Join leading ocular/uveal melanoma specialists for a patient-friendly webinar ... Read More| AIM at Melanoma Foundation
Tell the FDA Why New Treatment Options Matter When promising new cancer treatments are denied approval, the impact is felt far beyond a single diagnosis. Patients with all types of cancer—melanoma, breast, lung, pancreatic, ovarian, and more—are left with fewer chances to survive and fewer ways to fight their disease. For many living with advanced cancer, standard therapies work for ... Read More| AIM at Melanoma Foundation
For AIM at Melanoma, August is all about getting ready for a busy September and fall. While August/September is Back to School for some, it’s Back to What We Do Best here at AIM. So, what have we been working on, and what is up and coming? Read on to find out! First and most importantly, researchers, patients, medical providers, ... Read More The post Back to AIM: Advocacy, Walks, and Fall Initiatives in Melanoma appeared first on AIM at Melanoma Foundation.| AIM at Melanoma Foundation
Side Effect Central is a series of articles designed to help patients with melanoma and their caregivers understand the side effects that typically accompany melanoma treatments. Our goal is to explain what side effects to expect during treatment and to encourage communication with your medical team about these side effects. Side effects can range from mild to very serious, and ... Read More The post Side Effect Central – Cutaneous Squamous Cell Carcinoma and Keratoacanthoma appeared first ...| AIM at Melanoma Foundation
Focus on TIGIT Immunotherapy What Is Immunotherapy? Many people with healthy immune systems still develop cancer. Sometimes the immune system doesn’t see the cancer cells as foreign because the cells aren’t different enough from normal cells, and sometimes the immune system recognizes the cancer cells, but the response might not be strong enough to destroy the cancer. Immunotherapy is a treatment approach ... Read More The post New Advances in Phase 3 Treatments for Melanoma appeared fi...| AIM at Melanoma Foundation
FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a treatment for advanced melanoma that had shown promise in clinical trials. RP1 (vusolimogene oderparepvec) is an oncolytic immunotherapy given in combination with nivolumab (Opdivo). RP1 + nivolumab would have been a second-line treatment for patients with advanced melanoma that did ... Read More| AIM at Melanoma Foundation
Difficult News and A Reminder of the Impact of Melanoma Today we would like to acknowledge the recent death of Brandon Blackstock from melanoma. Our sympathy goes out to his family, friends, and fans. His passing is a reminder that melanoma is a serious health threat that can affect us all. Melanoma is the most aggressive type of skin cancer, ... Read More The post Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness appeared first on AIM at Melanoma Foundation.| AIM at Melanoma Foundation
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio® (imsapepimut and etimupepimut, adjuvanted). The trial evaluated Cylembio in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), vs. pembrolizumab alone as a first-line treatment in 407 patients with unresectable or metastatic (advanced) ... Re...| AIM at Melanoma Foundation
What is Sunscreen? Sunscreen protects the skin from absorbing ultraviolet (UV) rays. Sunscreen products contain one or more UV filters as active ingredients. There are two kinds of UV rays that can affect the skin: UVA and UVB. In the U.S., sunscreen is considered an over-the-counter drug and is regulated by the U.S. Food and Drug Administration. The preventive benefit ... Read More| AIM at Melanoma Foundation
What is Ultraviolet Radiation? Ultraviolet (UV) radiation is a type of energy produced by the sun and by artificial sources, such as tanning beds. UV radiation is the main cause of melanoma and other skin cancers such as basal cell carcinoma and squamous cell carcinoma. The sun’s UV rays can reach a person three ways: directly from the sun; scattered ... Read More| AIM at Melanoma Foundation
